ESTRO 2024 - Abstract Book

S859

Clinical - CNS

ESTRO 2024

these were undergone to surgery before RS. Clinical response at 3 months was obtained in 31/38 patients (82%) particularly complete response and partial response in 16/38 (42%) and 15/38 (39%), respectively. Clinical stability in 6/38 (16%) and progression in 1/38 (3%) patients, respectively. After a median follow-up of 8,5 years (range, 0,3-13,5 years), clinical response was 92% +/- 4%, 71% +/-7%, and 53% +/- 9% at 1, 2 and 5 years, respectively; median time to onset of response was 3 months (range, 1-16 months), median duration of response was 62 months (range, 37-158 months). About clinical response at univariate analysis, there was a significant statistical difference for patients treated with dose < 70 Gy or ≥ 70 Gy (p=0,0036) in favour of higher dose. Moreover, achieving a complete response does not affect clinical response duration at univariate analysis. Patients without clinical response were re-irradiated in 4 cases after a median time of 5 years (range, 1-8 years), and 2 underwent to surgery. No acute toxicity was registered, only 1 patient (4%) developed hearing loss after 12 years as chronic toxicity.

Conclusion:

RS is a therapeutic option efficacy and safety for neuropathic pain of neuralgia trigeminal. The dose administered at least 70 Gy is crucial to obtain a satisfying clinical response, and also prolonged response time.

Keywords: neuralgia trigeminal radiosurgery

1772

Digital Poster

EVALUATION OF RECURRENCE PATTERNS AFTER POSTOPERATIVE RADIOSURGERY FOR BRAIN METASTASES

Luca Visani, Niccolò Bertini, Isacco Desideri, Daniela Greto, Gabriele Simontacchi, Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti, Anna Peruzzi, Carolina Orsatti, Chiara Mattioli, Giulio Frosini, Luca Burchini, Luisa Caprara, Maria Grazia Carnevale, Icro Meattini, Lorenzo Livi

Azienda Ospedaliero Universitaria Careggi, Università di Firenze, Radiation Oncology, Firenze, Italy

Purpose/Objective:

Brain metastases (BM) account for more than half of all newly diagnosed intracranial malignancies. Surgical excision is a valuable treatment option, especially in case of symptomatic lesions. Since patients who undergo surgical resection of BM have a 50-60% of risk of local relapse within the first 12 months, postoperative radiosurgery (SRS) to the surgical cavity has become the standard of care, supported by data from two randomized trials showing decreased risk of neurocognitive decline compared to whole brain radiation therapy (WBRT) and improved local control compared with observation.